Tirzepatide is one of the few peptides with a dose schedule printed on an FDA label. This guide puts that schedule first, then lays out every amount tested in the major trials, then covers the numbers that circulate for compounded and gray-market vials, and says which of those figures are just copies of each other.
Ask PeptideBlog about any peptide
Quick answer: On the FDA labels for Zepbound and Mounjaro, tirzepatide starts at 2.5 mg injected under the skin once a week for 4 weeks, then goes to 5 mg. After that the dose can rise in 2.5 mg steps, with at least 4 weeks on each dose.[1][2] Zepbound maintenance doses are 5, 10 or 15 mg weekly (10 or 15 mg for sleep apnea), and the maximum is 15 mg weekly.[1] Doses are fixed milligram amounts, not set by body weight. The large trials tested the same 5, 10 and 15 mg.[5] Amounts above 15 mg, “microdosing” below 2.5 mg and research-vial protocols are not label doses.
Figures on this page summarize amounts and schedules reported in published research, prescribing information or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Every studied or reported tirzepatide amount at a glance
One table, three kinds of rows. The first three are the labels. The next group is the trial arms that produced the evidence. The last group is the non-label material people search for, each tagged with how good its source is.
Swipe the table sideways to see every column.
| Source | Population | Route | Amount | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|---|
| Zepbound label, weight reduction | Adults with obesity, or overweight plus at least one weight-related condition | Subcutaneous | Start 2.5 mg, then 5 mg; further steps of 2.5 mg. Maintenance 5, 10 or 15 mg. Maximum 15 mg. | Once weekly | 2.5 mg for 4 weeks; at least 4 weeks on a dose before each step | Prescribing information (label)[1] |
| Zepbound label, sleep apnea | Adults with moderate to severe obstructive sleep apnea and obesity | Subcutaneous | Same start and steps. Maintenance 10 or 15 mg. Maximum 15 mg. | Once weekly | Same escalation rule | Prescribing information (label)[1] |
| Mounjaro label | Adults and children aged 10 and older with type 2 diabetes | Subcutaneous | Start 2.5 mg, then 5 mg; steps of 2.5 mg. Maximum 15 mg in adults, 10 mg in pediatric patients. | Once weekly | 2.5 mg for 4 weeks, then at least 4 weeks per step | Prescribing information (label)[2] |
| SURMOUNT-1 | Adults with obesity, no diabetes (2,539) | Subcutaneous | 5, 10 and 15 mg | Once weekly | 72 weeks including a 20 week escalation | Published human clinical trial (Tier 1)[5] |
| SURMOUNT-2 | Adults with obesity and type 2 diabetes (938) | Subcutaneous | 10 and 15 mg | Once weekly | 72 weeks | Published human clinical trial (Tier 1)[6] |
| SURMOUNT-3 | Adults who lost 5% or more on a 12 week lifestyle program (579) | Subcutaneous | Maximum tolerated dose, 10 or 15 mg | Once weekly | 72 weeks | Published human clinical trial (Tier 1)[7] |
| SURMOUNT-4 | Adults with obesity, no diabetes (783 entered, 670 randomized) | Subcutaneous | Maximum tolerated dose, 10 or 15 mg, then continue or switch to placebo | Once weekly | 36 weeks open label, then 52 weeks | Published human clinical trial (Tier 1)[8] |
| SURMOUNT-5 | Adults with obesity, no diabetes (751) | Subcutaneous | Maximum tolerated dose, 10 or 15 mg, versus semaglutide 1.7 or 2.4 mg | Once weekly | 72 weeks, open label | Published human clinical trial (Tier 1)[9] |
| SURMOUNT-MAINTAIN | Adults with obesity who lost weight on tirzepatide (378 randomized) | Subcutaneous | Maximum tolerated dose (10 or 15 mg), then continue it, drop to 5 mg, or switch to placebo | Once weekly | 60 weeks, then 52 weeks (week 112) | Published human clinical trial (Tier 1)[10] |
| SURMOUNT-OSA (two trials) | Adults with moderate to severe sleep apnea and obesity | Subcutaneous | Maximum tolerated dose, 10 or 15 mg | Once weekly | 52 weeks | Published human clinical trial (Tier 1)[11] |
| SUMMIT | Adults with heart failure (ejection fraction 50% or more) and obesity (731) | Subcutaneous | Up to 15 mg | Once weekly | Median follow-up 104 weeks | Published human clinical trial (Tier 1)[12] |
| SURPASS-1 to -5 | Adults with type 2 diabetes (478 to 1,995 per trial) | Subcutaneous | 5, 10 and 15 mg (SURPASS-4 reports 10 and 15 mg in its abstract) | Once weekly | 40 to 52 weeks | Published human clinical trial (Tier 1)[13][14][15][16][17] |
| SURPASS-CVOT | Adults with type 2 diabetes and heart disease (13,165 randomized) | Subcutaneous | Up to 15 mg, versus dulaglutide 1.5 mg | Once weekly | Median follow-up about 4 years | Published human clinical trial (Tier 1) (summary of the NEJM paper)[18] |
| SURPASS-PEDS | Ages 10 to under 18 with type 2 diabetes (99) | Subcutaneous, single-dose pen | 5 and 10 mg | Once weekly | 30 weeks double blind | Published human clinical trial (Tier 1)[19] |
| Phase 1 program | Healthy adults and adults with type 2 diabetes (142) | Subcutaneous | Single doses 0.25 to 8 mg; weekly doses 0.5 to 10 mg (healthy) and 0.5 to 15 mg (diabetes) | Single dose, or once weekly | 4 weeks of weekly dosing | Published human clinical trial (Tier 1)[20] |
| Higher-dose phase 2 (NCT06037252) | Adults with type 2 diabetes, obesity and BMI 35 or more, on metformin (414) | Subcutaneous | Arms named “High Dose 1” and “High Dose 2”; milligram amounts not in the records I could read | Once weekly | Primary endpoint week 44, extension to week 80 | Registered human trial (Tier 2)[21] |
| Compounded tirzepatide (clinic-reported) | Patients of telehealth and compounding programs | Subcutaneous | Platform chart repeats 2.5 to 15 mg in 2.5 mg steps; FDA also reports doses above the label | Weekly | Steps of 4 weeks “as tolerated” | Clinic or vendor reported (Tier 6)[24][29] |
| “Microdosing” | No trial population | Subcutaneous | No standard amount. One clinic says “1.25 mg or lower”; an EHR study used repeated 2.5 mg prescriptions | Weekly | Not consistently reported | Practitioner reported (Tier 5); observational (Tier 2)[28][30] |
| Gray-market “research” vials | Not applicable | Subcutaneous (as described by sellers and wikis) | Wiki charts: 1.25 to 5 mg per injection; 7.5 to 10 mg “moderate maintenance”; 5 to 15 mg per week split into two injections | Weekly, or two injections per week | Listed as “ongoing”; one guide says 20 weeks minimum | Community reported (Tier 6); origin unclear[31][32][33] |
| Weight-based dosing (mg per kg) | Not applicable | Not applicable | None on either label; doses are fixed milligram amounts | Not applicable | Not applicable | Prescribing information (label)[1][2] |
Trial sizes are as randomized or treated in each paper. SURPASS-CVOT randomized 6,586 to tirzepatide and 6,579 to dulaglutide.[18] Zepbound comes as pens, single-dose vials, multi-dose vials and KwikPens, and the Mounjaro label lists its own presentations.[1][2] Pediatric Mounjaro is for type 2 diabetes only; Zepbound is labeled for adults.[1][2]
Where these figures come from
Almost every tirzepatide number online traces to one document, so the sorting is easier than for most peptides.
- Most-reported figure: start at 2.5 mg, step up by 2.5 mg every 4 weeks, top out at 15 mg. Its origin is Lilly’s label and trial protocols. The SURPASS-3 and SURPASS-5 papers describe the same 2.5 mg start with 2.5 mg increases every 4 weeks, and SURMOUNT-1 reached its top dose inside a 20 week escalation.[1][2][5][15][17]
- Human evidence: strong for 5, 10 and 15 mg once weekly in obesity, type 2 diabetes, sleep apnea, heart failure and heart disease. None is published above 15 mg.[5][12][18]
- Animal evidence: the only animal data I opened is a mouse program inside the 2018 discovery paper. Its abstract gives no milligram or per-kilogram amounts, and animal amounts should never be converted into human ones.[20]
- Practitioner figures: one clinic commentary describes “microdosing” as starting at “1.25 mg or lower” and cites no study by name.[30]
- Community and vendor figures: 1.25 mg increments, a 7.5 to 10 mg “moderate maintenance” band, and splitting a weekly total into two injections appear on wiki and guide pages with no original source. One page credits “400 community reports” without listing them.[31][32][33]
- Websites repeating each other: the vial math (milligrams in the vial divided by milliliters of water, then units on a syringe) shows up nearly identically on four sites. Agreement there only means the arithmetic is right. It says nothing about whether the schedule on top of it is safe or even real.[29][31][33][35]
- Weight-based conversions: none exist. Both labels and every trial above use fixed milligram doses, including the pediatric one.[1][2][19]
Detailed human data
What the labels say, as written
Both labels were last revised in August 2026.[1][2] The wording below is quoted or closely paraphrased from the dosage section of each. The Zepbound and Mounjaro labels cover the same drug, so the dose rules match, with different indications and a lower pediatric maximum on Mounjaro.
Swipe the table sideways to see every column.
| Item | Zepbound (weight reduction, sleep apnea) | Mounjaro (type 2 diabetes) |
|---|---|---|
| Starting dose | 2.5 mg injected subcutaneously once weekly for 4 weeks. “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”[1] | “The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly.”[2] |
| First step | “After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.”[1] | The same step: 5 mg after 4 weeks.[2] |
| Step size and interval | Increases in 2.5 mg increments “after at least 4 weeks on the current dose.”[1] | Increases of 2.5 mg after at least 4 weeks on the current dose, if more glycemic control is needed.[2] |
| Maintenance doses | Weight reduction: 5, 10 or 15 mg once weekly. Sleep apnea: 10 or 15 mg once weekly. The label says to consider response and tolerability, and to consider a lower maintenance dose if one is not tolerated.[1] | No fixed maintenance list in the sections I read; dose is raised as needed up to the maximum.[2] |
| Maximum | 15 mg once weekly for all indications.[1] | 15 mg once weekly in adults; 10 mg once weekly in pediatric patients.[2] |
| Missed dose | Give it as soon as possible within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip it and give the next dose on the regular day.[1] | Same 4 day (96 hour) rule.[2] |
| Changing the weekly day | Allowed if at least 3 days (72 hours) separate the two doses.[1] | Same 3 day (72 hour) rule.[2] |
| Timing | Once weekly at any time of day, with or without meals; rotate injection sites.[1] | Once weekly at any time of day, with or without meals.[2] |
| Weight-based dose | None. Fixed milligram doses.[1] | None. Fixed milligram doses.[2] |
Neither label’s dosage section gives a dose that converts between tirzepatide and another drug, and neither tells patients how to switch from one product to another. The Zepbound label says not to use it with other tirzepatide products or any GLP-1 receptor agonist.[1]
The tirzepatide dosage chart, as the label allows it
People search for a week-by-week chart, so here is one built directly from the label rule. It shows the earliest week each dose can start if every step is taken at the 4 week minimum. Many prescribers go slower, and the label sets a floor, not a schedule. The 20 week escalation in SURMOUNT-1 lines up with this path.[1][5]
Swipe the table sideways to see every column.
| Dose | Earliest start | Label status |
|---|---|---|
| 2.5 mg | Week 1 | Initiation only; not a maintenance dose for Zepbound[1] |
| 5 mg | Week 5 | First maintenance option[1] |
| 7.5 mg | Week 9 | Step dose on the way up[1] |
| 10 mg | Week 13 | Maintenance option[1] |
| 12.5 mg | Week 17 | Step dose on the way up[1] |
| 15 mg | Week 21 | Maintenance option and maximum[1] |
Pens, vials and KwikPens: what is in each
The label lists two families of products. Single-dose pens and single-dose vials each hold one dose in 0.5 mL. Multi-dose vials and the single-patient-use KwikPen hold four doses, each 0.6 mL.[1] Lilly says Zepbound vials and KwikPens are sold through its self-pay pharmacy channel, LillyDirect, and the maker’s February 2026 release says the KwikPen delivers a month of weekly doses in one device.[3][36]
Swipe the table sideways to see every column.
| Presentation | Strengths | Volume per dose | Notes from the label or maker |
|---|---|---|---|
| Single-dose pen | 2.5, 5, 7.5, 10, 12.5, 15 mg | 0.5 mL | Discard if not used within 21 days after leaving the refrigerator (Feb 2026 label text)[39] |
| Single-dose vial | 2.5, 5, 7.5, 10, 12.5, 15 mg | 0.5 mL | Needs a syringe; label gives “a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose” as an example. New syringe and needle each time.[1] |
| Multi-dose vial or KwikPen, 2.5 mg strength | 10 mg per 2.4 mL (4.17 mg/mL) | 0.6 mL, four doses | Opened vial or KwikPen discarded after 30 days in total (Feb 2026 label text)[39] |
| Multi-dose vial or KwikPen, 5 mg strength | 20 mg per 2.4 mL (8.33 mg/mL) | 0.6 mL, four doses | KwikPen not recommended for self-injection by people who are visually impaired[1] |
| Multi-dose vial or KwikPen, 7.5 mg strength | 30 mg per 2.4 mL (12.5 mg/mL) | 0.6 mL, four doses | Patients must be trained on the specific presentation they receive[1] |
| Multi-dose vial or KwikPen, 10 mg strength | 40 mg per 2.4 mL (16.7 mg/mL) | 0.6 mL, four doses | If the prescribed presentation changes, retrain and use the new Instructions for Use[1] |
| Multi-dose vial or KwikPen, 12.5 mg strength | 50 mg per 2.4 mL (20.8 mg/mL) | 0.6 mL, four doses | Label: vials and KwikPens each contain 4 doses[1] |
| Multi-dose vial or KwikPen, 15 mg strength | 60 mg per 2.4 mL (25 mg/mL) | 0.6 mL, four doses | Label: vials and KwikPens each contain 4 doses[1] |
The Mounjaro label also states that its KwikPen is not recommended for self-administration by pediatric patients.[2]
Tirzepatide units on a syringe, on the label’s own vials
The label gives volumes, never “units.” A standard insulin syringe is marked in units, 100 to the milliliter, so the label volumes work out to 50 units for a 0.5 mL single-dose vial dose and 60 units for a 0.6 mL multi-dose vial dose. That is plain arithmetic on label numbers, and a pharmacist should confirm it for the product in your hand.[1] On Lilly’s own vials the volume stays the same at every strength, because the concentration changes instead. That is the opposite of the community vial tables further down, where the concentration is fixed by how much water someone adds and the volume changes with the dose. Our insulin syringe guide and units explainer cover the markings, and the reconstitution calculator does the math without presetting any dose.
SURMOUNT-1: the dose-response trial
SURMOUNT-1 is the cleanest look at what each maintenance dose did. It randomized 2,539 adults with obesity, or overweight plus a weight-related condition, and no diabetes, to 5, 10 or 15 mg once weekly or placebo for 72 weeks, with a 20 week escalation.[5] Mean starting weight was 104.8 kg.
Swipe the table sideways to see every column.
| Weekly dose | Mean weight change (95% CI) | Lost 5% or more | Lost 20% or more | Stopped for side effects |
|---|---|---|---|---|
| 5 mg | 15.0% loss (14.2 to 15.9) | 85% | Not stated in abstract | 4.3% |
| 10 mg | 19.5% loss (18.5 to 20.4) | 89% | 50% | 7.1% |
| 15 mg | 20.9% loss (19.9 to 21.8) | 91% | 57% | 6.2% |
| Placebo | 3.1% loss (1.9 to 4.3) | 35% | 3% | 2.6% |
Source: published abstract.[5] The treatment-regimen estimand counts everyone as randomized, including people who stopped treatment, so it is more conservative than an on-treatment analysis.
What the dose response shows
More milligrams did produce more weight loss, with fading returns. Going from 5 to 10 mg added 4.5 percentage points of average loss. Going from 10 to 15 mg added 1.4 more, and the confidence intervals for those two arms nearly touch.[5] The same ordering held in SURMOUNT-2 in people with type 2 diabetes, where 10 and 15 mg produced 12.8% and 14.7% loss versus 3.2% on placebo.[6] Group averages hide wide individual spread, which is why the label tells prescribers to weigh response and tolerability instead of aiming for the top dose.[1]
The other weight and heart trials, dose arms and results
Swipe the table sideways to see every column.
| Trial | Doses | Headline result as published | Estimand or basis |
|---|---|---|---|
| SURMOUNT-2[6] | 10 and 15 mg vs placebo, 72 weeks | 12.8% and 14.7% weight loss vs 3.2% on placebo | Treatment-regimen |
| SURMOUNT-3[7] | Maximum tolerated dose (10 or 15 mg) vs placebo, 72 weeks, after a 12 week lifestyle program | 18.4% additional loss vs 2.5% gain on placebo | Treatment-regimen |
| SURMOUNT-4[8] | Maximum tolerated dose for 36 weeks, then continue vs placebo for 52 weeks | Week 36 to 88: 5.5% further loss on tirzepatide vs 14.0% regain on placebo; 89.5% vs 16.6% kept at least 80% of the loss | Randomized withdrawal |
| SURMOUNT-5[9] | Tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mg, each at maximum tolerated dose, 72 weeks | 20.2% vs 13.7% weight loss; waist 18.4 cm vs 13.0 cm smaller | Open label, least-squares means |
| SURMOUNT-OSA[11] | Maximum tolerated dose (10 or 15 mg) vs placebo, 52 weeks, two trials | Apnea-hypopnea index fell by 25.3 and 29.3 events per hour vs 5.3 and 5.5 on placebo | Change from baseline |
| SUMMIT[12] | Up to 15 mg vs placebo, median follow-up 104 weeks | Heart-failure death or worsening: 9.9% vs 15.3% (hazard ratio 0.62, 95% CI 0.41 to 0.95) | Time to first event |
| SURPASS-CVOT[18] | Up to 15 mg vs dulaglutide 1.5 mg, median about 4 years | Death from heart causes, heart attack or stroke: 12% vs 13% (hazard ratio 0.92); non-inferior, superiority not shown (p=0.09) | Non-inferiority design |
Type 2 diabetes: the SURPASS program
The SURPASS trials tested 5, 10 and 15 mg against placebo, semaglutide, insulin degludec or insulin glargine. In SURPASS-3 and SURPASS-5 the protocol started tirzepatide at 2.5 mg and raised it by 2.5 mg every 4 weeks until the assigned dose, the pattern the label later adopted.[15][17]
Swipe the table sideways to see every column.
| Trial | Duration | 5 mg | 10 mg | 15 mg | Comparator |
|---|---|---|---|---|---|
| SURPASS-1[13] | 40 weeks | 1.87 lower | 1.89 lower | 2.07 lower | Placebo: 0.04 higher |
| SURPASS-2[14] | 40 weeks | 2.01 lower | 2.24 lower | 2.30 lower | Semaglutide 1 mg: 1.86 lower |
| SURPASS-3[15] | 52 weeks | 1.93 lower | 2.20 lower | 2.37 lower | Insulin degludec: 1.34 lower |
| SURPASS-4[16] | 52 weeks | Not in abstract | 2.43 lower | 2.58 lower | Insulin glargine: 1.44 lower |
| SURPASS-5[17] | 40 weeks | 2.11 lower | 2.40 lower | 2.34 lower | Placebo: 0.86 lower (on insulin glargine) |
Children and teens had their own program. In SURPASS-PEDS, 99 participants aged 10 to under 18 received 5 mg, 10 mg or placebo by single-dose pen for 30 weeks; HbA1c fell 2.23 points in the pooled tirzepatide group while it rose 0.05 on placebo, and BMI fell 7.4% on 5 mg and 11.2% on 10 mg.[19] That trial is why Mounjaro’s pediatric maximum is 10 mg.[2]
Low doses: what has been measured below the standard path
Two sets of data touch low or lowered doses. SURMOUNT-MAINTAIN is a randomized trial. After 60 weeks of open-label tirzepatide at the maximum tolerated dose (10 or 15 mg), 378 adults were assigned 3:3:2 to keep that dose, drop to 5 mg, or switch to placebo for 52 more weeks. By week 112 the average loss from the starting weight was 21.9% on the maximum tolerated dose, 16.6% on 5 mg and 9.9% on placebo; rescue treatment was needed by 8%, 25% and 67%.[10] The authors call 5 mg a possible alternative to stopping, not a replacement for staying on the full dose.
The second is the electronic health record study by Murugadoss and colleagues in Biology Methods and Protocols (2026). They used patients with at least three separate 2.5 mg tirzepatide prescriptions spanning six months or more (1,016 people, out of 322,442 on tirzepatide) as a stand-in for staying at the lowest dose, and 814 semaglutide patients on 0.25 mg only. The authors say this pattern “may overlap with, but does not establish, intentional microdosing.” At 12 months the low-dose tirzepatide group had a mean weight change of 5.5% loss versus 2.2% for low-dose semaglutide, and higher 24 month rates of constipation (32.6% vs 22.4%), acute kidney injury (2.7% vs 0.4%) and muscle cramps (8.3% vs 4%).[28] It is observational, so it cannot say what the dose caused. For the full microdosing picture see the Atlas page on GLP-1 microdosing.
Tirzepatide vs semaglutide vs retatrutide, dose arms side by side
Only one randomized head-to-head exists. SURMOUNT-5 gave adults the maximum tolerated dose of each drug for 72 weeks and found 20.2% loss on tirzepatide versus 13.7% on semaglutide.[9] Retatrutide, Lilly’s triple agonist, is not approved, and the company says it is available only to trial participants. Its 80 week TRIUMPH-1 topline (company-reported, 2,339 adults) used 4, 9 and 12 mg and showed 17.6%, 23.7% and 25.0% average loss on the treatment-regimen estimand versus 3.9% on placebo.[23] A Lilly head-to-head of retatrutide against tirzepatide, TRIUMPH-5, has an 80 week endpoint and a registered primary completion in November 2026.[22] Until it reads out, comparing the two means comparing different trials. See the retatrutide entry, the semaglutide entry and petrelintide against semaglutide and tirzepatide.
Swipe the table sideways to see every column.
| Drug and trial | Doses | Week | Mean weight loss | Basis |
|---|---|---|---|---|
| Tirzepatide, SURMOUNT-1[5] | 5, 10, 15 mg | 72 | 15.0%, 19.5%, 20.9% (placebo 3.1%) | Treatment-regimen |
| Tirzepatide vs semaglutide, SURMOUNT-5[9] | Tirzepatide 10 or 15 mg; semaglutide 1.7 or 2.4 mg | 72 | 20.2% vs 13.7% | Open-label head-to-head |
| Retatrutide, TRIUMPH-1[23] | 4, 9, 12 mg | 80 | 17.6%, 23.7%, 25.0% (placebo 3.9%) | Treatment-regimen, company topline |

Animal research amounts
The 2018 discovery paper from Lilly describes tirzepatide (then LY3298176) in cell assays and in mice, where chronic dosing cut body weight and food intake more than a GLP-1 receptor agonist did. The abstract states the effects but gives no dose per kilogram or per mouse.[20]
Swipe the table sideways to see every column.
| Species or model | Amount | Frequency | Duration | Route | Source |
|---|---|---|---|---|---|
| Mice, diet and glucose studies | Not stated in the abstract | Not stated | “Chronic” administration | Not stated | Published animal research (Tier 3)[20] |
Animal amounts do not translate into human doses, so none are converted here. Anyone quoting a “mouse dose scaled to humans” for tirzepatide is doing a calculation no source on this page supports.
Compounded, microdose and research-vial protocols
This is the material most people are really searching for when they type “tirzepatide dosage chart” or “tirzepatide units.” None of it is clinical evidence, and several sources contradict their own math. Here is what each says, with the source type next to it.
Compounded tirzepatide: what pharmacies and clinics state, and what FDA states
Compounded tirzepatide is made by a pharmacy for an individual patient and is not FDA approved. FDA said the tirzepatide shortage was resolved on 19 December 2024, which ended the main reason broad compounding was allowed.[26] FDA’s page on unapproved GLP-1 drugs says that as of 31 May 2026 it had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and that the counts are likely too low because state-licensed pharmacies that are not outsourcing facilities do not have to report.[24][25] Report counts cannot show how common a problem is. FDA also describes patients measuring and injecting wrong doses, clinicians miscalculating doses, and reports of “more product per dose, more frequent dosing, or faster titration” than the approved labels describe.[24] The Atlas covers the rules in compounded versus brand-name medicines.
On the clinic side, a telehealth platform’s dosing chart restates the label ladder (2.5, 5, 7.5, 10, 12.5, 15 mg at 4 weeks a step “as tolerated”) and says compounded tirzepatide is “typically limited to 15 mg per week.” It has no named author and says compounded product is “not interchangeable with brand-name products.”[29]
Source-by-source table
Swipe the table sideways to see every column.
| Reported protocol | Amount reported | Frequency | Duration | Route | Source type | Source |
|---|---|---|---|---|---|---|
| Compounded vial chart | 2.5, 5, 7.5, 10, 12.5, 15 mg; examples at 5, 10, 15 and 20 mg/mL (for example 25 units for 2.5 mg at 10 mg/mL) | Weekly | 4 weeks per step, “as tolerated” | Subcutaneous | Clinic or vendor reported (Tier 6); no named author | Telehealth platform chart[29] |
| “Standard” research-vial guide | Start 2.5 mg; typical 5 to 10 mg; “maximum” 12.5 to 15 mg. Vials: 10 mg + 2 mL (5 mg/mL), 30 mg + 3 mL (10 mg/mL), 40 mg + 4 mL (10 mg/mL) | Weekly | 20 weeks minimum; 6+ months long term | Subcutaneous | Community or vendor reported (Tier 6); no named author, no citations | Peptide guide site[33] |
| Wiki dose chart and “community protocols” | 1.25, 2.5, 3.75, 5 mg per injection; “moderate maintenance” 7.5 to 10 mg; split-dose 5 to 15 mg per week in two injections | Weekly, or two injections 3 to 4 days apart | “Ongoing”; reconstituted vial used within 28 days | Subcutaneous | Community reported (Tier 6); origin unclear (“400 community reports” not listed) | Peptide wiki, 30 mg and 10 mg pages[31][32] |
| Vial-size and unit tables | Vial sizes 5, 10, 15, 30, 45, 60 mg (20 mg “depending on the pharmacy”); 30 mg + 3 mL = 10 mg/mL called the “recommended setup” | Weekly | Step timing not given on that page | Subcutaneous | Community or affiliate-linked tool site (Tier 6); author says he is not a doctor | GLP-1 planner site[35] |
| “Microdosing” | “Typically starting at 1.25 mg or lower”; also writes “0.5-15 mg weekly” for standard protocols | Weekly (standard) | Not specified | Subcutaneous | Practitioner commentary (Tier 5); names no study; says no clinical evidence of meaningful weight loss | Clinic article[30] |
| Gray-market vial example | “10 vials of 30mg each”; 30 mg + 3 mL gives 10 mg/mL, so 25 units = 2.5 mg | Weekly | Not specified | Subcutaneous | Vendor-adjacent explainer (Tier 6); origin unclear | Peptide guide site[34] |
These pages disagree with each other and sometimes with themselves. One lists doses of 150 and 200 units, which cannot fit in a 100-unit, 1 mL insulin syringe.[33] A wiki page says tirzepatide comes as a pre-filled pen needing no mixing in one section and gives a mixing calculator in another.[31][32] Treat them as descriptions of what circulates, not as protocols.
Why vial concentration is the whole problem
One of the guide pages makes the point itself. If a vial sold as 30 mg actually held 20 mg, drawing 25 units from a 10 mg/mL mix would deliver 1.67 mg instead of 2.5 mg; if it held 45 mg, the same draw would deliver 3.75 mg.[34] The arithmetic is simple, and it shows why FDA lists unit, milliliter and milligram confusion among the dosing errors it has seen.[24] Our reconstitution guide and water volume guide explain the mechanics without recommending any dose.
Cost per milligram, since sources bring it up
Dollar-per-milligram talk comes from two directions. The maker’s self-pay page lists monthly prices for four weekly doses of each strength: $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 to 15 mg when a refill happens within 45 days, with higher regular prices otherwise.[4] Dividing a month’s price by a month’s milligrams gives the table below. It is arithmetic on the maker’s list, not how the product is sold or a suggestion to buy any strength.
Swipe the table sideways to see every column.
| Strength | Price for 4 doses | Milligrams in 4 doses | Price per mg |
|---|---|---|---|
| 2.5 mg | $299 | 10 | $29.90 |
| 5 mg | $399 | 20 | $19.95 |
| 7.5 mg | $449 | 30 | $14.97 |
| 10 mg | $449 | 40 | $11.23 |
| 12.5 mg | $449 | 50 | $8.98 |
| 15 mg | $449 | 60 | $7.48 |
Prices are “starting at” figures from the maker page and apply to vials and KwikPens alike; the page says regular prices of $499 (7.5 mg) and $699 (10, 12.5 and 15 mg) apply if the prescription is not refilled within 45 days.[4] Prices change often. For gray-market prices, the two pages I read give unsourced and mutually inconsistent figures (one table says $35 to $50 a month, another says $320 to $600 for a 30 mg vial protocol), so no per-milligram number is offered for them.[33][34] The Atlas keeps a cost tool for current prices.
Escalation, timing, duration and routes
- Route: subcutaneous injection in the abdomen, thigh or back of the upper arm, with sites rotated. Both labels list injection only.[1][2]
- Frequency: once weekly, on any day, any time of day, with or without food. The day can be changed if doses are at least 72 hours apart.[1]
- Why weekly: the Zepbound label reports an elimination half-life of about 5 to 6 days, a median time to peak of 24 hours, absolute bioavailability of 80% and steady-state levels after 4 weeks of weekly dosing.[1] The 4 week minimum between steps matches that steady-state time, though the label does not state it as the reason.
- Duration: the weight-loss label says to “maintain weight reduction long term.” In SURMOUNT-4, switching to placebo after 36 weeks led to regain of 14.0% of body weight, while continuing kept losing.[1][8]
- Dose reduction: the label says to consider a lower maintenance dose if one is not tolerated.[1] SURMOUNT-MAINTAIN tested dropping to 5 mg on purpose and found less maintained loss than staying on the full dose.[10]
- Missed dose: within 4 days (96 hours), give it; after that, skip it.[1][2]
- Switching products: neither label gives a conversion from semaglutide, from another tirzepatide presentation, or between Zepbound and Mounjaro. They say only to retrain patients when the presentation changes.[1][2] The Atlas has a page on switching between Wegovy, Zepbound and Mounjaro, and one on Zepbound vs Wegovy.
The question “how long should I stay on each dose?” has a floor in the label (at least 4 weeks before a step) and no ceiling. SURMOUNT-1 used a steady 4 week cadence for 20 weeks.[5] For what to expect while stepping up, the Atlas has a week-by-week side effects page and a page on how long GLP-1 medicines take to work.
Tirzepatide was not studied in the Italian GLP-1 discontinuation cohort that reported a death hazard ratio of 4.81, because the data ended before it reached the market. The analysis of that study covers what the number does and does not show.
Combinations and stacks
Swipe the table sideways to see every column.
| Category | Combination | What exists |
|---|---|---|
| Formally studied | With metformin, sulfonylureas, SGLT2 inhibitors or basal insulin | SURPASS-2 to -5 tested tirzepatide on top of these in type 2 diabetes[14][15][16][17] |
| Formally studied | After an intensive lifestyle program | SURMOUNT-3 added tirzepatide after a 12 week program[7] |
| Formally studied | With ixekizumab in psoriatic arthritis with obesity | TOGETHER-PsA, an open-label phase 3b trial, gave tirzepatide with ixekizumab for 52 weeks. Weight loss was objective; the week 52 joint results were exploratory (analysis, paper) |
| Registered, not reported | Tirzepatide plus bimagrumab (Phase 2); tirzepatide plus eloralintide (Phase 3, not yet recruiting) | Registry records only[37][38] |
| Labeled caution | Another tirzepatide product or any GLP-1 receptor agonist | Zepbound label says not to combine[1] |
| Labeled caution | Insulin or insulin secretagogues | Mounjaro label advises considering a lower secretagogue dose[2] |
| Practitioner or vendor reported | Compounded tirzepatide with vitamin B12 or niacinamide | Lilly-authored lab tests found a widespread impurity in tirzepatide/B12 products; clinical effects unknown[27] |
| Community reported | Peptide “stacks” with tirzepatide | No dosing source meeting this site’s standard was identified |
Side effects, quality and sourcing risks
Side effects track the dose. The Zepbound label’s pooled table for weight-reduction trials shows nausea in 8% on placebo and 25%, 29% and 28% on 5, 10 and 15 mg, diarrhea in 8% versus 19%, 21% and 23%, vomiting in 2% versus 8%, 11% and 13%, and constipation in 5% versus 17%, 14% and 11%.[1] In SURMOUNT-1 most digestive events were mild to moderate and came mainly during dose escalation.[5] SUMMIT saw 6.3% stop for adverse events on tirzepatide versus 1.4% on placebo.[12] The label carries further warnings I do not reproduce here, including pancreatitis, gallbladder disease and a boxed thyroid warning, so read the full text.[1]
Quality risks apply to anything not made under the approval. FDA says it has warned companies selling tirzepatide and other incretin drugs labeled “not for human consumption” with dosing instructions, and that the quality of such products is unknown.[24] Lilly scientists reported a widespread impurity in compounded tirzepatide/B12 products bought in the U.S., with unknown clinical effect.[27] Mislabeled strength is the practical risk in dosing, because the whole unit calculation rests on the number printed on the vial. A report of “30 mg” is a claim, not a measurement.
Regulatory and development status
Tirzepatide is FDA approved, with an initial U.S. approval year of 2022.[1] As of the August 2026 labels, Zepbound is indicated to reduce excess body weight and maintain the reduction in adults with obesity, or with overweight plus a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.[1] Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and patients aged 10 and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk.[2] Lilly announced the Zepbound KwikPen label expansion on 23 February 2026.[3] Retatrutide, the follow-on Lilly triple agonist, is investigational.[23] Compounded and gray-market tirzepatide is not FDA approved.[24] For brand details see the Atlas pages for Zepbound, Mounjaro and tirzepatide, and our tirzepatide research entry. Label text on this page was read from the prescribing information revised in August 2026.
What is not public
- Milligram amounts for the higher-dose Phase 2 arms in NCT06037252, and any efficacy or safety result from them.[21]
- Any randomized trial of tirzepatide “microdosing” for weight loss. None was identified.[28][30]
- A controlled comparison of compounded and approved tirzepatide at matched doses. Reports and lab tests exist, but not that trial.[24][27]
- How long people can safely stay on 5 mg after losing weight on a higher dose; SURMOUNT-MAINTAIN followed them for 52 weeks.[10]
- A conversion between tirzepatide doses and semaglutide or retatrutide doses. No label or trial supplies one.[1][2]
- The result of the retatrutide versus tirzepatide head-to-head, due after November 2026.[22]
- The identity, purity and true content of any given research vial. Only a lab test of that vial could say.
Frequently asked questions
What is the tirzepatide dosage?
On the FDA labels, tirzepatide starts at 2.5 mg injected under the skin once weekly for 4 weeks, then 5 mg. It can rise in 2.5 mg steps after at least 4 weeks on each dose. Zepbound maintenance doses are 5, 10 or 15 mg (10 or 15 mg for sleep apnea), and the maximum is 15 mg weekly.[1][2]
What is a tirzepatide dosage chart?
It is the label ladder: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, with at least 4 weeks on each dose before a step. Taking every step at the 4 week minimum puts the first week on each dose at week 1, 5, 9, 13, 17 and 21. The label sets a minimum interval, not a required timetable.[1]
Is tirzepatide 2.5 mg a real treatment dose?
On the Zepbound label, 2.5 mg is the starting dose and “is not approved as a maintenance dosage.” The first maintenance option for weight reduction is 5 mg.[1]
How long on each tirzepatide dose?
At least 4 weeks on the current dose before each increase, according to both labels. There is no upper limit in the label, and the trials used a 4 week step. Prescribers choose the maintenance dose by response and tolerability.[1][2][5]
Is tirzepatide dosed by body weight?
No. Both labels use fixed milligram doses with no milligram-per-kilogram rule, including for patients aged 10 and older on Mounjaro.[1][2]
What happens if you miss a tirzepatide dose?
The labels say to give the missed dose as soon as possible within 4 days (96 hours). After more than 4 days, skip it and take the next dose on the regular day. The weekly day can be changed if doses are at least 72 hours apart.[1][2]
How many units is 2.5 mg of tirzepatide on a syringe?
It depends entirely on the concentration of the product. On Lilly’s labeled single-dose vials every dose is 0.5 mL, which is 50 units on a 100-unit insulin syringe, at every strength. In a mixed research or compounded vial, units change with the mg per mL. For example, a source lists 25 units for 2.5 mg at 10 mg/mL. Confirm with the pharmacist who supplied the product.[1][29]
Is tirzepatide microdosing proven?
No trial has tested it for weight loss. The closest data are an observational record study of people who stayed on repeated 2.5 mg prescriptions and SURMOUNT-MAINTAIN, where a randomized 5 mg step-down group kept less weight off than the full-dose group.[10][28]
How does tirzepatide dosing compare with semaglutide?
Tirzepatide goes from 2.5 mg to a 15 mg maximum in 2.5 mg steps. In the SURMOUNT-5 head-to-head, the maximum tolerated doses were 10 or 15 mg for tirzepatide and 1.7 or 2.4 mg for semaglutide, with 20.2% versus 13.7% weight loss at 72 weeks. The milligram numbers are not interchangeable between the drugs.[9]
Tirzepatide vs retatrutide: which has the higher dose?
Retatrutide trials used 4, 9 and 12 mg, and it is unapproved. Because the drugs differ, the milligram numbers cannot be compared. Lilly’s head-to-head trial, TRIUMPH-5, has not reported.[22][23]
Can you switch between Zepbound, Mounjaro or another GLP-1 and keep the same dose?
Neither label gives a conversion, and no randomized switching trial was found. Zepbound and Mounjaro are the same medicine under two labels, but a prescriber decides any change of product or dose.[1][2]
Bottom line
Tirzepatide dosing has more published backing than almost any other peptide on the web. What is genuinely published: a label ladder from 2.5 to 15 mg weekly, with at least 4 weeks per step, and randomized evidence for 5, 10 and 15 mg across weight, diabetes, sleep apnea, heart failure and cardiovascular outcomes.[1][2][5][12][18] The dose response is real and tapers, 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg in SURMOUNT-1.[5] What is merely reported online: microdosing, 1.25 mg steps, 7.5 to 10 mg “moderate maintenance,” twice-weekly splits and vial tables whose arithmetic is often right but whose protocols have no original source.[30][31][33] What is speculative: any amount above 15 mg, where only registry placeholders exist.[21] The biggest practical hazard is not the milligram number. It is a vial that does not contain what its label says, drawn up with unit math nobody checked. Tirzepatide is approved; compounded and research-vial versions are not.
Keep reading

Sources
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection prescribing information. Revised 8/2026. https://uspl.lilly.com/zepbound/zepbound.html?s=pi Prescribing information (label)
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection prescribing information. Revised 8/2026. https://uspl.lilly.com/mounjaro/mounjaro.html?s=pi Prescribing information (label)
- Eli Lilly and Company. Zepbound KwikPen news release. 23 February 2026. https://investor.lilly.com/node/53951 Maker announcement
- LillyDirect. Zepbound self-pay page (KwikPen and single-dose vial prices). https://lilly.com/lillydirect/medicines/zepbound Maker page
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038 PMID 35658024. NCT04184622. Published human clinical trial (Tier 1). Funded by Eli Lilly.
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. https://doi.org/10.1016/S0140-6736(23)01200-X PMID 37385275. Published human clinical trial (Tier 1). Funded by Eli Lilly.
- Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2023;29(11):2909-2918. https://doi.org/10.1038/s41591-023-02597-w PMID 37840095. Published human clinical trial (Tier 1).
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945 PMID 38078870. Published human clinical trial (Tier 1).
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. https://doi.org/10.1056/NEJMoa2416394 PMID 40353578. Published human clinical trial (Tier 1). Open label. Funded by Eli Lilly.
- Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet. 2026;407(10545):2305-2318. Published 12 May 2026. https://doi.org/10.1016/S0140-6736(26)00656-2 PMID 42119587. NCT06047548. Published human clinical trial (Tier 1). Funded by Eli Lilly.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205. https://doi.org/10.1056/NEJMoa2404881 PMID 38912654. Published human clinical trial (Tier 1). Funded by Eli Lilly.
- Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med. 2025;392(5):427-437. https://doi.org/10.1056/NEJMoa2410027 PMID 39555826. Published human clinical trial (Tier 1). Funded by Eli Lilly.
- Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of tirzepatide in type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155. https://doi.org/10.1016/S0140-6736(21)01324-6 PMID 34186022. Published human clinical trial (Tier 1).
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519 PMID 34170647. Published human clinical trial (Tier 1).
- Ludvik B, Giorgino F, Jodar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec (SURPASS-3). Lancet. 2021;398(10300):583-598. https://doi.org/10.1016/S0140-6736(21)01443-4 PMID 34370970. Published human clinical trial (Tier 1).
- Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021;398(10313):1811-1824. https://doi.org/10.1016/S0140-6736(21)02188-7 PMID 34672967. Published human clinical trial (Tier 1).
- Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine (SURPASS-5). JAMA. 2022;327(6):534-545. https://doi.org/10.1001/jama.2022.0078 PMID 35133415. Published human clinical trial (Tier 1).
- Nicholls SJ, Bhatt DL, Buse JB, et al. Tirzepatide versus dulaglutide on cardiovascular outcomes in type 2 diabetes (SURPASS-CVOT). N Engl J Med. Figures read from the American College of Cardiology journal summary dated 7 January 2026, not from the paper itself; full citation to be confirmed. https://www.acc.org/latest-in-cardiology/journal-scans/2026/01/07/14/20/surpass-cvot Published human clinical trial (Tier 1) (secondary summary of the paper).
- Hannon TS, Chao LC, Barrientos-Perez M, et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS). Lancet. 2025;406(10511):1484-1496. https://doi.org/10.1016/S0140-6736(25)01774-X PMID 40975112. NCT05260021. Published human clinical trial (Tier 1).
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. https://doi.org/10.1016/j.molmet.2018.09.009 PMID 30473097. NCT02759107. Published animal research (Tier 3) and Phase 1 human trial (Tier 1).
- ClinicalTrials.gov. NCT06037252: A study of investigational tirzepatide (LY3298176) doses in participants with type 2 diabetes and obesity. Sponsor: Eli Lilly. https://clinicaltrials.gov/study/NCT06037252 Registered human trial (Tier 2). Active, not recruiting; no results posted.
- ClinicalTrials.gov. NCT06662383: A study of retatrutide compared to tirzepatide in adults who have obesity (TRIUMPH-5). Sponsor: Eli Lilly. https://clinicaltrials.gov/study/NCT06662383 Registered human trial (Tier 2). Primary endpoint week 80; no results posted.
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). News release, 21 May 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss Company announcement (sponsor-reported, not peer reviewed).
- U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Page dated 1 October 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Regulator statement.
- Becker’s Hospital Review. FDA warns clinicians on compounded GLP-1s amid 1,700+ safety reports. Reported 8 September 2026. https://www.beckershospitalreview.com/glp-1s/fda-warns-on-compounded-glp-1s-amid-1700-safety-reports/ News report of regulator statement.
- Frier Levitt. FDA determines (again) the tirzepatide shortage is resolved: what this means for 503A and 503B compounding. https://www.frierlevitt.com/articles/fda-determines-again-the-tirzepatide-shortage-is-resolved-what-this-means-for-503a-and-503b-compounding Law-firm summary of regulator action.
- Jordan B, Arbogast L, Clemens M, et al. A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications. Expert Opin Drug Saf. 2026;25(5):837-845. https://doi.org/10.1080/14740338.2026.2663185 PMID 42010938. Laboratory research (Tier 4). Authors are Eli Lilly employees.
- Murugadoss K, Venkatakrishnan AJ, Soundararajan V. Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide. Biol Methods Protoc. 2026;11(1):bpag048. https://doi.org/10.1093/biomethods/bpag048 PMID 42857675. Human observational research (Tier 2). Authors from nference Inc.
- FormBlends Editorial Research. Tirzepatide dosing chart: units to mg. Published 1 May 2026. https://formblends.com/articles/injection-technique/tirzepatide-dosing-chart-units-to-mg Clinic or vendor reported (Tier 6). Telehealth platform; no named author.
- Caplan B. Tirzepatide microdosing: clinical evidence and safety. CED Clinic. Published 10 June 2026. https://cedclinic.com/tirzepatide-microdosing-evidence-safety-clinical-insights/ Practitioner reported (Tier 5). Names no study.
- Peptide Protocol Wiki Team. Tirzepatide 30 mg dosing calculator. https://www.peptideprotocolwiki.com/tools/dosing-calculator/tirzepatide-30mg Community reported (Tier 6); origin unclear.
- Peptide Protocol Wiki Team. Tirzepatide 10 mg dosing calculator. https://www.peptideprotocolwiki.com/tools/dosing-calculator/tirzepatide-10mg Community reported (Tier 6); origin unclear.
- SeekPeptides. Tirzepatide dosing guide: complete protocol for all strengths. Published 20 December 2025. https://www.seekpeptides.com/blog/articles/tirzepatide-dosing-guide Community or vendor reported (Tier 6). No named author; no citations.
- SeekPeptides. Grey market tirzepatide. Published 22 February 2026. https://www.seekpeptides.com/blog/articles/grey-market-tirzepatide Community or vendor reported (Tier 6). Unsourced price and test figures not reproduced here.
- GLP3 Planner (Hill T). Compounded tirzepatide reference: reconstitution chart. https://glp3planner.com/resources/tirzepatide-reconstitution-chart Community reported (Tier 6). Page carries affiliate links.
- Lilly Medical Information. How do I get Zepbound vials or multidose KwikPens? Date of last review 23 February 2026. https://medical.lilly.com/us/products/answers/how-do-i-get-zepbound-tirzepatide-vials-or-multidose-kwikpens-250061 Maker page.
- ClinicalTrials.gov. NCT06643728: Bimagrumab and tirzepatide, alone or in combination, in adults with obesity or overweight without type 2 diabetes (Phase 2). Sponsor: Eli Lilly. https://clinicaltrials.gov/study/NCT06643728 Registered human trial (Tier 2).
- ClinicalTrials.gov. NCT07881432: Phase 3 study of LY900043 (eloralintide and tirzepatide) in adults with obesity without type 2 diabetes. Sponsor: Eli Lilly. https://clinicaltrials.gov/study/NCT07881432 Registered human trial (Tier 2). Not yet recruiting.
- U.S. Food and Drug Administration. ZEPBOUND prescribing information, supplement 042 label PDF (revised 02/2026), storage text in Section 16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf Prescribing information (label), earlier 2026 version.
Educational reference only, not medical advice. This page documents amounts on prescribing information and in published and registered research, plus figures circulating online. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.